Suchergebnisse - (Person:"Curtin, Nicola")

PubPharm (27)

1

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy

enthalten in: Nature reviews. Clinical oncology | 2019

von Curtin, N. | Drew, Y. | Sharma-Saha, S.

CommentOn: Nature. 2019 Jul;571(7766):576-579. - PMID 31292550

2

Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors

enthalten in: Biochemical pharmacology | 2019

von Mukhopadhyay, A. | Drew, Y. | Matheson, E. | +4

3

Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases

enthalten in: British journal of pharmacology | 2018

von Berger, N. | Besson, V. | Boulares, A. | +19

4

PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS

enthalten in: NMR in biomedicine | 2017

von Almeida, G. | Bawn, C. | Galler, M. | +6

5

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

enthalten in: Cancer discovery | 2017

von de Bono, J. | Ramanathan, R. | Mina, L. | +13

6

Strategies Employed for the Development of PARP Inhibitors

enthalten in: Methods in molecular biology (Clifton, N.J.) | 2017

von Canan, S. | Maegley, K. | Curtin, N.

7

The Use of PARP Inhibitors in Cancer Therapy : Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients

enthalten in: Methods in molecular biology (Clifton, N.J.) | 2017

von Shall, S. | Gaymes, T. | Farzaneh, F. | +2

8

Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis : Mechanism and Potential Role for PARP Inhibitors

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2016

von Kotsopoulos, I. | Kucukmetin, A. | Mukhopadhyay, A. | +2

9

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

enthalten in: British journal of cancer | 2016

von Drew, Y. | Ledermann, J. | Hall, G. | +14

CommentIn: Br J Cancer. 2016 Mar 29;114(7):713-5. - PMID 27022824

10

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

enthalten in: Oncotarget | 2015

von Herriott, A. | Tudhope, S. | Junge, G. | +13